JP2005536531A5 - - Google Patents

Download PDF

Info

Publication number
JP2005536531A5
JP2005536531A5 JP2004527368A JP2004527368A JP2005536531A5 JP 2005536531 A5 JP2005536531 A5 JP 2005536531A5 JP 2004527368 A JP2004527368 A JP 2004527368A JP 2004527368 A JP2004527368 A JP 2004527368A JP 2005536531 A5 JP2005536531 A5 JP 2005536531A5
Authority
JP
Japan
Prior art keywords
hydrogen atom
hydroxy
ophthalmic composition
macrolide compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004527368A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005536531A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2003/010105 external-priority patent/WO2004014373A1/en
Publication of JP2005536531A publication Critical patent/JP2005536531A/ja
Publication of JP2005536531A5 publication Critical patent/JP2005536531A5/ja
Pending legal-status Critical Current

Links

JP2004527368A 2002-08-09 2003-08-08 アレルギー性疾患を処置する為のfk506誘導体を含む医薬組成物及びその使用 Pending JP2005536531A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40206102P 2002-08-09 2002-08-09
PCT/JP2003/010105 WO2004014373A1 (en) 2002-08-09 2003-08-08 Pharmaceutical compositions comprising fk506 derivatives and the ir use for the treatment of allergic diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010203075A Division JP2011012071A (ja) 2002-08-09 2010-09-10 アレルギー性疾患を処置する為のfk506誘導体を含む医薬組成物及びその使用

Publications (2)

Publication Number Publication Date
JP2005536531A JP2005536531A (ja) 2005-12-02
JP2005536531A5 true JP2005536531A5 (enExample) 2006-09-28

Family

ID=31715781

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004527368A Pending JP2005536531A (ja) 2002-08-09 2003-08-08 アレルギー性疾患を処置する為のfk506誘導体を含む医薬組成物及びその使用
JP2010203075A Pending JP2011012071A (ja) 2002-08-09 2010-09-10 アレルギー性疾患を処置する為のfk506誘導体を含む医薬組成物及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010203075A Pending JP2011012071A (ja) 2002-08-09 2010-09-10 アレルギー性疾患を処置する為のfk506誘導体を含む医薬組成物及びその使用

Country Status (10)

Country Link
US (1) US20050239813A1 (enExample)
EP (1) EP1536793A1 (enExample)
JP (2) JP2005536531A (enExample)
KR (1) KR20050054913A (enExample)
CN (1) CN1674896A (enExample)
AU (1) AU2003256068A1 (enExample)
BR (1) BR0313425A (enExample)
CA (1) CA2495103A1 (enExample)
MX (1) MXPA05001575A (enExample)
WO (1) WO2004014373A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040019034A (ko) * 2001-07-06 2004-03-04 수캄포 아게 인터루킨 2 억제제 및 항미생물제를 포함하는 국소 투여용조성물
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
CA2539324A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
BRPI0607606B1 (pt) 2005-02-09 2021-06-22 Santen Pharmaceutical, Co., Ltd. Formulação líquida
EP1904056B1 (en) 2005-07-18 2009-04-29 Minu, L.L.C. Use of a macrolide to restore corneal sensation
CN1965825B (zh) * 2005-11-17 2011-07-06 洪晶 一种治疗眼部免疫性疾病及抑制增殖、新生血管的眼表用药
CN101605529B (zh) 2006-02-09 2013-03-13 参天制药株式会社 稳定制剂及它们的制备和使用方法
BRPI0709016A2 (pt) 2006-03-23 2011-06-21 Macusight Inc formulações e métodos para doenças ou condições relacionadas com a permeabilidade vascular
KR100891313B1 (ko) 2007-08-17 2009-03-31 (주) 제노텍 담체로 작용하는 흡착성 수지의 제공에 의한 트리사이클로화합물의 생산 및 추출 방법
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
KR101632042B1 (ko) * 2014-06-30 2016-06-21 주식회사 인트론바이오테크놀로지 Fk506 유도체를 함유하는 크립토코쿠스 속 곰팡이 및 칸디다 속 곰팡이에 의한 진균 감염을 치료하기 위한 약제학적 조성물 및 그의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU635286B2 (en) * 1989-07-05 1993-03-18 Astellas Pharma Inc. Aqueous liquid composition for external use
CA2054983A1 (en) * 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
JP3158437B2 (ja) * 1991-04-26 2001-04-23 藤沢薬品工業株式会社 眼疾患に対するマクロライド化合物の使用
US7063857B1 (en) * 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
WO2000066122A1 (en) * 1999-04-30 2000-11-09 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
AR033151A1 (es) * 2001-04-12 2003-12-03 Sucampo Pharmaceuticals Inc Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares
KR20040019034A (ko) * 2001-07-06 2004-03-04 수캄포 아게 인터루킨 2 억제제 및 항미생물제를 포함하는 국소 투여용조성물
US20050070468A1 (en) * 2001-11-21 2005-03-31 Sucampo Ag Use of fk506 and analogues for treating allergic diseases

Similar Documents

Publication Publication Date Title
JP2005536531A5 (enExample)
JP2005502621A5 (enExample)
JP2022081661A5 (enExample)
JP2005539088A5 (enExample)
JP2007538024A5 (enExample)
JP2004530691A5 (enExample)
EP1857457A3 (en) Benzimidazole derivative and its use as AII receptor antagonist
JP2003509349A5 (enExample)
JP2002535323A5 (enExample)
JP2008510828A5 (enExample)
JP2012510502A5 (enExample)
JP2005527593A5 (enExample)
JP2015025011A5 (enExample)
JP2020507589A5 (enExample)
JP2014514290A5 (enExample)
JP2019513745A5 (enExample)
JP2004529928A5 (enExample)
JPWO2023195529A5 (enExample)
JP2013515037A5 (enExample)
AR048808A1 (es) Pirrolocarbazoles fusionados
JP2010514733A5 (enExample)
JP2016500653A5 (enExample)
AR065297A1 (es) Formulaciones biodisponibles de compuestos heterociclicos
JP2005526773A5 (enExample)
JP2008521908A5 (enExample)